Free to Breathe

Video about a lung cancer clinical trial by the New England Journal of Medicine

Results of a clinical trial of an EGFR-agent called osimertinib was recently published in the New England Journal of Medicine. A short video was made to discuss this important trial. Based on the results, it is expected that the FDA will approve osimertinib as first-line treatment for patients with EGFR-mutated lung cancer. The drug is already approved (brand name Tagrisso) for patients whose lung cancer has the T790M mutation.


You may also like...